ARMP logo

ARMATA PHARMACEUTICALS INC

ARMPNYSE AMERICAN
🏆 #3842 by market capEarnings Nov 18US Equity
——
Quote unavailable
🔔
Track ARMP
Get earnings, price moves & breaking news on Telegram
Track
24h—
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$130M
Small Cap
📈Revenue Growth (YoY)
-19.3%
Declining
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
23.3x
Expensive
Otter Score
—
Insufficient data
No chart data available for ARMP.

Trading Snapshot

Day Range
—
52-Week Range
$2.75 – $14.98
Volume (shares)
—
Avg Volume (shares)
—
Shares Outstanding
37.2M
Next Earnings
2026-11-18

Fundamentals Snapshot

Annual Revenue
$5M
Last Q Revenue
$3M
P/E Ratio
—
P/S Ratio
23.3x
EPS (TTM)
$-6.12
Dividend Yield
—
Dilution (1yr)
−38.5%
ARMP logo

ARMATA PHARMACEUTICALS INC

ARMP
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$5M▼ −5.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
68.8%▼ −112.2% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$31M▼ −26.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$26M▼ −33.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
36.3M▼ −38.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$279M▼ −$162M YoY
StockOtter · stockotter.space

About ARMATA PHARMACEUTICALS INC

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline are several significant candidates: AP-SA02, designed for the treatment of Staphylococcus aureus bacteremia; AP-PA02, targeting Pseudomonas aeruginosa; and AP-PA03, intended to address pneumonia. Additionally, Armata has forged a collaborative agreement with Merck & Co. to further the development of synthetic bacteriophage candidates aimed at specific, yet unrevealed, infectious disease agents. The company's main offices are located in Marina del Rey, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

News unavailable.